VERTEX PHARMACEUTICALS INC / MA

VRTX 10-K · Q4 2025
API behind this page

VRTX Q4 2025 request

Playground key active
Request URL /api/financials?ticker=VRTX&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue 3,190 2,912 +9.5%
Show Product Lines breakouts
CASGEVY 54.3 8 +578.8%
Manufactured Product Other 237.4 191.2 +24.2%
Product 3,190 2,912 +9.5%
Product · Accumulated Translation Adjustment -37.1 24.5 -251.4%
TRIKAFTA/KAFTRIO 2,572.5 2,720.8 -5.5%
Show Business Segments breakouts
Pharmaceuticals 3,190 2,912 +9.5%
Show — breakouts
Revenue 2,091.3 1,837.2 +13.8%
Revenue 885.9 832 +6.5%
Revenue 243.5 242.8 +0.3%
Cost of Revenue 466 423.4 +10.1%
Show Product Lines breakouts
Product · Pharmaceuticals 190.8 152.4 +25.2%
Royalty · Pharmaceuticals 275.2 271 +1.5%
Show Collaborative Arrangements by Agreement [Axis] breakouts
CRISPR JDCA 37.2 26 +43.1%
Research And Development Expense Excluding Acquired In Process Cost 973.7 998.7 -2.5%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 56.5 87.5 -35.4%
Show Business Segments breakouts
Pharmaceuticals 56.5 87.5 -35.4%
Selling, General & Administrative 487 377.6 +29.0%
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 0.9 -1.2 +175.0%
Total Costs & Expenses 1,984.1 1,886 +5.2%
Operating Income 1,205.9 1,026 +17.5%
Investment Income Interest And Dividend 121.9 128.2 -4.9%
Show Business Segments breakouts
Pharmaceuticals 121.9 128.2 -4.9%
Interest Expense -3.3 -2.8 -17.9%
Other Non-Operating Income (Expense) 6.5 -14.9 +143.6%
Show Equity Components breakouts
Accumulated Translation Adjustment · Foreign Exchange Forward -7.5 27.4 -127.4%
Income Before Taxes 1,331 1,136.5 +17.1%
Income Tax Expense (Benefit) 139.9 223.5 -37.4%
Show Business Segments breakouts
Pharmaceuticals 139.9 223.5 -37.4%
Net Income 1,191.1 913 +30.5%
Show Business Segments breakouts
Pharmaceuticals 1,191.1 913 +30.5%
Show Equity Components breakouts
Retained Earnings 1,191.1 913 +30.5%
EPS (Basic) 4.69 3.53 +32.9%
EPS (Diluted) 4.64 3.53 +31.4%
Wtd Avg Shares (Basic) -0.7 -0.2 -250.0%
Wtd Avg Shares (Diluted) -0.6 -0.2 -200.0%
General & Administrative (Q) — — —
Show Business Segments breakouts
Pharmaceuticals 168.2 144 +16.8%
Comprehensive Income 1,239.7 1,012 +22.5%
Other Comprehensive Income 48.6 99 -50.9%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent 50.6 142.7 -64.5%
Accumulated Net Unrealized Investment Gain Loss -0.5 -44.1 +98.9%
Accumulated Other Comprehensive Income 48.6 99 -50.9%
Accumulated Translation Adjustment -1.5 0.4 -475.0%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash & Cash Equivalents 5,084.8 4,569.6 +11.3%
Marketable Securities (Current) 1,523.3 1,546.3 -1.5%
Accounts Receivable 2,052.8 1,609.4 +27.6%
Inventory 1,686.8 1,205.4 +39.9%
Prepaid Expenses & Other Current Assets 853.3 665.7 +28.2%
Total Current Assets 11,201 9,596.4 +16.7%
Non-Current Assets
Goodwill 1,088 1,088 0.0%
Deferred Tax Assets 2,897.9 2,331.1 +24.3%
Operating Lease Right-of-Use Assets 1,562.7 1,356.8 +15.2%
Show Real Estate And Accumulated Depreciation Description Of Property breakouts
Fan Pier Leases [Member] 847.9 — —
Jeffrey Leiden Center for Biologics, Cell and Genetic Therapies Campus 296.7 — —
Marketable Securities (Non-Current) 5,712.3 5,107.9 +11.8%
Other Non-Current Assets 1,236.6 999.3 +23.7%
Total Assets 25,643 22,533.2 +13.8%
Intangible Assets (Q) — — —
Show Finite Lived Intangible Assets By Major Class breakouts
Employment Contracts 3.7 6.2 -40.3%
Marketing Related Intangible Assets 195.9 216.1 -9.3%
Other Assets
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization 1,520.3 1,227.8 +23.8%
Intangible Assets Net Excluding Goodwill 424.2 825.9 -48.6%
Current Liabilities
Accounts Payable 461.7 413 +11.8%
Accrued Liabilities 2,971.2 2,788.6 +6.5%
Other Liabilities Current 428.3 363 +18.0%
Total Current Liabilities 3,861.2 3,564.6 +8.3%
Non-Current Liabilities
Operating Lease Liabilities 1,846.5 1,544.4 +19.6%
Show Real Estate And Accumulated Depreciation Description Of Property breakouts
Fan Pier Leases [Member] 1 — —
Jeffrey Leiden Center for Biologics, Cell and Genetic Therapies Campus 296.7 — —
Other Non-Current Liabilities 1,269.5 1,014.6 +25.1%
Total Liabilities 6,977.2 6,123.6 +13.9%
Stockholders' Equity
Common Stock 2.5 2.6 -3.8%
Additional Paid In Capital Common Stock 5,119.2 6,672.4 -23.3%
Accumulated Other Comprehensive Income -15.9 127.8 -112.4%
Retained Earnings 13,560 9,606.8 +41.2%
Total Stockholders' Equity 18,665.8 16,409.6 +13.7%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent -87.1 111 -178.5%
Accumulated Net Unrealized Investment Gain Loss 34 7.1 +378.9%
Accumulated Other Comprehensive Income -15.9 127.8 -112.4%
Accumulated Translation Adjustment 37.2 9.7 +283.5%
Additional Paid In Capital 5,119.2 6,672.4 -23.3%
Common Stock 2.5 2.6 -3.8%
Retained Earnings 13,560 9,606.8 +41.2%
Total Liabilities & Equity 25,643 22,533.2 +13.8%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Stock-Based Compensation 157.6 167.8 -6.1%
Depreciation & Amortization 55.7 46.5 +19.8%
Increase Decrease In Other Deferred Liability 30.5 51.6 -40.9%
Other Non-Cash Items 23.1 16.4 +40.9%
Change in Accounts Receivable -99.4 69 -244.1%
Change in Inventory -77.4 -147.5 +47.5%
Change in Prepaid & Other Assets -250.6 -164.6 -52.2%
Change in Accounts Payable 38.3 8.4 +356.0%
Increase Decrease In Accrued Liabilities And Other Operating Liabilities -664.5 -320.1 -107.6%
Increase Decrease In Other Operating Liabilities 105.8 -5.4 +2059.3%
Net Cash from Operations 498 584.6 -14.8%
Investing Activities
Purchases of Investments -1,230.6 -2,158.6 +43.0%
Proceeds From Sale And Maturity Of Available For Sale Securities 1,091.8 1,460.2 -25.2%
Capital Expenditures -149.4 -92.6 -61.3%
Other Investing Activities -15.9 -30.9 +48.5%
Net Cash from Investing -288.1 -821.9 +64.9%
Financing Activities
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 54 34.3 +57.4%
Share Repurchases -128.4 -417.9 +69.3%
Tax Withholding for Share Compensation -2.5 -7.3 +65.8%
Finance Lease Principal Payments -1.4 -1.3 -7.7%
Proceeds From Payments For Other Financing Activities 1.1 0.9 +22.2%
Net Cash from Financing -77.2 -391.3 +80.3%
Supplemental
Income Taxes Paid 389.4 271.8 +43.3%
Interest Paid 3 2.7 +11.1%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 7.3 -47.3 +115.4%
Net Change in Cash 140 -675.9 +120.7%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 5,087.8 4,572.2 +11.3%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key